Prelude Capital Management, LLC I Mab Transaction History

Prelude Capital Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$1.54 - $2.37 $73,476 - $113,077	47,712 Added 142.21%	81,262 $151,000
Q4 2023 Feb 14, 2024	SELL	$1.21 - $1.9 $7,164 - $11,249	-5,921 Reduced 15.0%	33,550 $63,000
Q3 2023 Nov 14, 2023	BUY	$1.18 - $3.06 $46,575 - $120,781	39,471 New	39,471 $52,000
Q4 2022 Feb 14, 2023	BUY	$3.22 - $4.86 $35,497 - $53,576	11,024 Added 70.58%	26,644 $111,000
Q3 2022 Nov 14, 2022	SELL	$4.01 - $12.34 $18,169 - $55,912	-4,531 Reduced 22.49%	15,620 $63,000
Q2 2022 Aug 15, 2022	BUY	$8.27 - $18.43 $166,648 - $371,382	20,151 New	20,151 $228,000
Q4 2020 Feb 16, 2021	SELL	$32.94 - $47.15 $88,938 - $127,305	-2,700 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$27.46 - $47.03 $74,142 - $126,981	2,700 New	2,700 $127,000

15.5M

56.4K

5.8K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $74.8M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.